PAIN SPA

PLANTAR FASCIITIS

From Diagnosis to Recovery: Evidence-Based Management

Comprehensive Clinical & Patient Guide for Clinicians and Patients

www.painspa.co.uk

Introduction & Epidemiology

Plantar fasciitis is the most common cause of plantar heel pain, affecting more than 2 million people annually in the United States alone. The American Academy of Family Physicians reports a lifetime prevalence of 10% in the general population, making it one of the most frequently encountered musculoskeletal conditions in primary care. Approximately 62% of the over 1 million annual patient visits in the US occur in primary care offices.

The condition is most prevalent in adults aged 45 to 64 years, generating 8.2 ambulatory visits per 1,000 persons annually. It affects women slightly more than men (annual incidence 1.19% vs 0.47%).

What is Plantar Fasciitis?

The plantar fascia is a thick band of connective tissue comprising three fascial bands — medial, central, and lateral — that originate from the plantar aspect of the calcaneus (heel bone) and insert at the metatarsophalangeal joints. During walking, the fascia tightens through the ‘windlass mechanism,’ stabilising the longitudinal arch of the foot.

Although commonly called ‘plantar fasciitis,’ the term plantar fasciopathy is more accurate because the condition is not primarily inflammatory. Repetitive mechanical overload leads to microscopic tears, predominantly at the plantar medial origin of the fascia, resulting in collagen degeneration, fibre disorientation, increased mucoid ground substance, and calcification.

Risk Factors

• Decreased ankle dorsiflexion — stepwise increase in risk as range of motion becomes more limited
• Elevated BMI — BMI >30 carries the greatest risk (OR 5.6, 95% CI 1.9–16.6)
• Prolonged standing at work — spending the majority of work time on feet (OR 3.6)
• Running — common in runners but can affect sedentary individuals too
• High-arch foot type and hamstring tightness
• Diabetes mellitus — linked to increased plantar fascia thickness and altered biomechanics

Clinical Presentation

The classic presentation is stabbing, non-radiating pain in the medial plantar heel that is worst with the first steps in the morning or after periods of rest. Pain often eases after initial ambulation, then returns with prolonged weight bearing.

Characteristic Symptoms

• Plantar heel pain most severe with first steps after rest (classic)
• Pain decreases after initial ambulation but returns with continued weight bearing
• Stabbing, non-radiating pain in the proximal medioplantar surface of the foot
• Pain worsening at the end of the day with prolonged standing

Physical Examination Findings

• Tenderness to palpation at the plantar medial heel / medial calcaneal tuberosity (most common finding)
• Pain exacerbated with passive extension of the toes (Windlass test)
• Decreased ankle dorsiflexion range of motion may be present

The Windlass test has high specificity (100%) but low sensitivity (14% non-weight-bearing; 32% weight-bearing). Despite low sensitivity, a positive test in a weight-bearing position is highly indicative of plantar fasciitis.

Natural History

Plantar fasciitis is typically self-limiting but may persist for months to years. With proper treatment, 80% of patients improve within 12 months. However, one study of 174 patients found 80.5% still had symptoms at 1-year follow-up and 44% at 15-year follow-up, with a mean symptom duration of 725 days for those who eventually resolved.

Diagnosis

The diagnosis of plantar fasciitis is primarily clinical, based on characteristic history and physical examination. Imaging is not required in most cases.

Clinical Diagnostic Approach

• Characteristic history of first-step morning pain after rest
• Tenderness at the medial calcaneal tuberosity on palpation
• Positive Windlass test (passive great toe extension)
• Pain with passive dorsiflexion of foot and toes
• Assessment of ankle dorsiflexion for asymmetry

When is Imaging Indicated?

Only 2% of imaged heels in patients with atraumatic plantar heel pain have radiographic findings that affect initial treatment. Imaging should be considered when:

• Symptoms do not improve with 6–8 weeks of conservative treatment
• Another pathology may be responsible (e.g., calcaneal stress fracture)
• The clinical diagnosis is unclear

Imaging Modalities

Ultrasonography

Plantar fascia thickness ≥4 mm (normal 2–4 mm) supports the diagnosis of plantar fasciitis. Ultrasound shows good sensitivity (80%) and specificity (88%) compared to MRI. It is superior to MRI in differentiating true fibre interruption and tearing from oedema, and allows dynamic assessment.

US elastography demonstrates even higher performance: sensitivity 95% and specificity 100% (vs conventional US sensitivity 66%, specificity 75%).

MRI

Considered the most sensitive imaging study for plantar fasciitis, showing T2-weighted hyperintensity at the origin of the plantar fascia and thickening. MRI should only be used when the clinical diagnosis is unclear, as some findings are non-specific and can be seen in asymptomatic individuals. MRI is also the most sensitive modality for stress fractures (sensitivity 68–99%).

Plain Radiographs

May rule out calcaneal stress fracture and other bony lesions. ‘Fluffy periostitis’ with ill-defined borders may suggest underlying spondyloarthropathy. Detection of heel spurs is of no value in confirming or excluding plantar fasciitis.

ACR Recommendation

The American College of Radiology (2025 Appropriateness Criteria) states that when radiographs are negative and plantar fasciitis or plantar fascia tear is suspected, MRI foot without IV contrast and ultrasound are equivalent imaging options. The choice should be guided by clinical context, local expertise, and availability.

Heel Spurs and Their Role in Plantar Fasciitis

Heel spurs (plantar calcaneal spurs) are bony outgrowths from the calcaneal tuberosity. They are present in approximately 50% of patients with plantar fasciitis but do not correlate well with symptoms and can also be found in asymptomatic individuals. As such, they should generally be considered an incidental radiographic finding.

Prevalence

In a study of 530 participants aged ≥50 years, plantar calcaneal spurs were identified in 26.5% of feet, while plantar fascia thickening was found in 47.3%. These features frequently coexisted (20.4% of feet had both), whereas isolated calcaneal spurs (without fascial thickening) were rare (only 6.0%).

Participants with plantar heel pain were more likely to have a combination of heel spurs and plantar fascial thickening (OR 2.16, P = 0.007). However, tenderness on palpation was not associated with spurs or thickening in isolation.

Spur Classification

Research has identified distinct spur types with different clinical relevance:

• Type A spurs — located superior to the plantar fascia insertion (outside the fascia)
• Type B spurs — located within the plantar fascia itself; associated with more severe plantar fasciitis on MRI, higher pain scores, increased inflammatory markers, and worse surgical outcomes

Clinical Implications

• Imaging to identify heel spurs is not necessary for diagnosis or management
• The presence or absence of a heel spur does not confirm or exclude plantar fasciitis
• When spurs and fascial thickening coexist, association with heel pain is stronger
• Treatment should focus on the plantar fasciitis itself, not the spur

Differential Diagnosis

Several conditions can mimic plantar fasciitis. A systematic approach is essential to avoid misdiagnosis.

Cannot-Miss Diagnoses

• Calcaneal osteomyelitis:
• Consider in patients with fever, elevated inflammatory markers, recent trauma, diabetes, or immunocompromise
• Metastatic bone disease to the calcaneus:
• Rare but important in patients with known malignancy or constitutional symptoms
• Acute deep vein thrombosis:
• May rarely present with referred heel pain, particularly in patients with thromboembolism risk factors

Screening for Spondyloarthropathy

Among patients with ‘refractory’ plantar fasciitis, 17.5% were diagnosed with peripheral spondyloarthritis in one study. These patients tend to be younger (mean age 22.8 vs 31.7 years) and predominantly male. Clinicians should screen for: inflammatory back pain, morning stiffness >30 minutes, bilateral symptoms, peripheral oligoarthritis, dactylitis, uveitis, psoriasis, inflammatory bowel disease, positive HLA-B27, elevated CRP/ESR, and family history of spondyloarthritis.

Evidence-Based Treatment Overview

The vast majority of patients improve with conservative management. Treatment follows a stepwise approach from first-line conservative measures through to minimally invasive interventions and, rarely, surgery.

Stretching and Strengthening Protocols

Stretching and strengthening remain the cornerstone of conservative treatment. Plantar fascia-specific stretching is more effective than general calf stretching alone, particularly for reducing the classic first-step pain.

A commonly used approach involves dorsiflexing the toes while seated in order to tension the plantar fascia directly. This is most useful when performed regularly and especially before taking the first steps in the morning.

Calf stretching is also important, particularly for the gastrocnemius and soleus, because reduced ankle dorsiflexion increases strain across the plantar fascia during gait.

In addition to stretching, progressive strengthening is essential. High-load exercises, including heel raises performed with the toes dorsiflexed, help improve load tolerance and support longer-term recovery. Strengthening of the intrinsic foot muscles and ankle stabilisers further improves foot mechanics and may reduce recurrence.

The aim is not simply to stretch the fascia, but to restore function and load tolerance through controlled, progressive rehabilitation.

Night Splints and Orthotics

Night splints are most useful in patients with chronic plantar fasciitis, especially when first-step morning pain is a prominent feature. By maintaining the ankle in dorsiflexion overnight, they help prevent shortening of the plantar fascia and may reduce pain on rising.

Orthotics aim to reduce mechanical load on the plantar fascia by supporting the arch and redistributing pressure. In practice, prefabricated orthotics are often as effective as custom devices and are usually the most practical starting point.

Both night splints and orthotics should be viewed as adjuncts rather than standalone treatments. Their main role is to support a broader rehabilitation programme that also includes stretching, strengthening, load modification, and footwear advice.

Manual therapy may also be helpful in selected patients, particularly where calf tightness, soft tissue restriction, or altered foot mechanics contribute to symptoms, but it should sit alongside an active rehabilitation programme rather than replace it.

Extracorporeal Shockwave Therapy (ESWT)

ESWT delivers pulsatile high-pressure soundwaves to the plantar fascia, typically performed by orthopaedists, physiatrists, or podiatrists. It is a well-established second-line treatment for recalcitrant plantar fasciitis.

Evidence

A landmark FDA multicentre RCT of 250 patients showed 69.2% VAS reduction with focused ESWT vs 34.5% with placebo (P = 0.0027). A meta-analysis of 7 RCTs (663 patients) confirmed superiority with improvement maintained up to 12 months.

A 2024 meta-analysis of 16 RCTs (1,121 patients) found ESWT superior to corticosteroid injections for pain reduction and foot function at 3 and 6 months. ESWT provides more durable relief than corticosteroids and should be considered before or instead of corticosteroid injection for chronic cases.

Standard Protocol (FDA-Approved)

• Energy flux density: 0.25 mJ/mm² (medium intensity)
• Impulses per session: 2,000
• Number of sessions: 3
• Interval: Weekly (7 days apart)
• Local anaesthesia: NOT recommended — reduces efficacy

Predictors of Success

A predictive model (overall success rate 66.9%, predictive accuracy 89.6%) identified the following factors associated with better ESWT outcomes:

• Lower baseline VAS score at first morning steps
• Absence of oedema
• Paradoxically, presence of a heel spur

Adverse Effects

ESWT is well-tolerated. Adverse effects are mild and transient: temporary pain during/after treatment, local swelling, slight erythema at the treatment site, and rare petechiae. No serious adverse events have been reported in major trials.

Injection Therapies

Corticosteroid Injections (CSI)

Corticosteroid injections are typically reserved for plantar fasciitis resistant to initial conservative non-invasive interventions. They provide rapid short-term pain relief but do not offer durable benefit.

Corticosteroid Options and Dosing

• Methylprednisolone: 20–80 mg
• Triamcinolone: 20–80 mg
• Betamethasone: 6 mg
• Dexamethasone: 4–8 mg

Efficacy

• Significant short-term pain relief at <1 month vs placebo (MD −6.38; 95% CI −11.13 to −1.64)
• Benefit does not persist beyond 1–6 months
• Inferior to PRP and dry needling at 13–52 week follow-up

Complications

• Plantar fascia rupture — approximately 2.4% of patients, more common after multiple injections
• Fat pad atrophy (risk increases with multiple injections)
• Infection, skin pigmentation changes, peripheral nerve injury, post-injection flare

Technique

Two approaches are used: (1) palpation-guided injection into the area of maximum tenderness at the medial calcaneal tuberosity; or (2) ultrasound-guided injection into the region of maximal fascia thickening. Ultrasound guidance is recommended to improve accuracy and potentially reduce complications. A posterior tibial nerve block with 2% lidocaine may be performed before the corticosteroid injection.

Platelet-Rich Plasma (PRP) Injections

PRP contains concentrated platelets and growth factors that promote tissue healing and regeneration, making it well-suited for the degenerative pathology underlying plantar fasciitis.

Efficacy

A multicentre RCT of 115 patients found that at 1-year follow-up, PRP produced significantly lower pain scores than corticosteroids (FFI Pain mean difference 14.4; 95% CI 3.2–25.6), with 84.4% of PRP patients achieving ≥25% improvement vs 55.6% of corticosteroid patients (P = 0.003). A 2025 retrospective cohort of 152 patients confirmed PRP superiority at 6 months. A network meta-analysis of 63 RCTs (4,170 participants) found PRP supports the best long-term improvements in function and plantar fascia thickness.

Technique

• Draw 20–60 mL of autologous venous blood
• Centrifuge to concentrate platelets
• Inject 2–3 mL of PRP under ultrasound guidance into the area of maximal plantar fascia thickening
• Avoid NSAIDs for at least 2 weeks post-injection (may impair healing response)

Botulinum Toxin A Injections

OnabotulinumtoxinA (Botox) is used off-label for plantar fasciitis. It is thought to reduce muscle spasm in intrinsic foot muscles, decreasing tension on the plantar fascia, and may also have direct analgesic effects. Relief can last up to 6 months.

Dosing Protocols

• 70 units total: 40 units into the tender heel region + 30 units into the most tender point of the foot arch
• Alternative: injection into flexor digitorum brevis and quadratus plantae under ultrasound guidance

Efficacy

A meta-analysis of 7 RCTs (305 participants) found significant pain reduction at 1 month and sustained functional improvement over 12 months. A network meta-analysis identified botulinum toxin A as providing the greatest short-term improvements in pain and plantar fascia thickness among all injection therapies evaluated.

Comparative Summary of Injection Therapies

Post-Injection Rehabilitation

Nerve Blocks for Plantar Fasciitis

Tibial Nerve Block

The posterior tibial nerve provides sensory innervation to the plantar heel via the medial calcaneal nerve and first branch of the lateral plantar nerve (Baxter’s nerve). Blocking this nerve provides effective analgesia to the plantar fascia region.

A 2026 RCT of 69 patients with ESWT-refractory plantar fasciitis found that ultrasound-guided tibial nerve block (TNB) provided clinically meaningful short-term analgesia comparable to corticosteroid injection, with significantly less procedural pain (P <0.001). TNB avoids intrafascial injection, reducing the risk of fascia rupture, and is a valuable option for patients in whom corticosteroids are contraindicated (e.g., diabetes, prior rupture).

Radiofrequency Nerve Ablation (RFNA)

RFNA uses thermal energy to create a lesion in sensory nerve branches supplying the painful heel, interrupting pain signal transmission. It is indicated for recalcitrant plantar fasciitis that has failed conservative treatment including ESWT and corticosteroid injections.

Two Main Techniques

• Conventional Radiofrequency Thermocoagulation (TRF):
• Temperature: 80°C for 90 seconds; creates thermal lesion (neurodestructive)
• Onset of analgesia: approximately 3 weeks
• Pulsed Radiofrequency (PRF):
• Temperature: 42°C for 240–360 seconds; neuromodulation without thermal destruction
• Onset of analgesia: ≤1 week; faster than TRF

Evidence

A prospective study of 35 feet with 2-year follow-up demonstrated dramatic improvements from pre-procedure VAS 9.2 ± 1.9 to 0.5 ± 1.3 at 1 month, maintained at 1.3 ± 1.8 at 2 years. 85.7% of patients rated treatment as very successful or successful. A 2024 prospective study comparing pulsed RFNA to surgery showed PRFA had shorter operative time, quicker return to activities, superior outcomes at 3 months, and lower complication rates, with similar 12-month outcomes.

Target Nerves

• First branch of the lateral plantar nerve (Baxter’s nerve) — most commonly implicated in neurogenic heel pain
• Medial calcaneal nerve branches — may be targeted alone or in combination

A diagnostic nerve block should precede RFNA to confirm neurogenic origin. In one study, 88% of patients who had failed both ESWT and steroid injections were successfully treated with RFNA after diagnostic confirmation.

Pulsed Radiofrequency (PRF) Ablation

PRF is a non-destructive neuromodulatory technique delivering short bursts of high-voltage current at low temperatures (42°C). It offers effective pain relief for chronic plantar fasciitis through modulation of pain signalling rather than thermal nerve destruction.

Mechanism of Action

• Anti-inflammatory effects — significantly reduces inflammatory cytokines (IL-6, IL-17, TNF-α, IFN-γ)
• Inhibition of neuropeptide secretion — impairs axonal transport, suppressing release of CGRP and substance P
• Ion channel modulation — affects Na/K ATPase, HCN channels, and P2X3 receptors
• C-fibre selectivity — primarily modulates unmyelinated C fibres while leaving myelinated nerve conduction intact
• Microglial suppression — attenuates spinal microglial/MAPK signalling involved in central sensitisation

Standard PRF Parameters

Advantages of PRF over Conventional TRF

• Non-destructive — preserves nerve architecture and function
• Faster onset — effective analgesia in ≤1 week vs 3 weeks for TRF
• Lower risk of complications — minimal risk of neuritis, dysaesthesia, or deafferentation pain
• Repeatable — can be repeated if pain recurs without cumulative nerve damage
• No motor weakness — selective effect on C fibres preserves motor function

Clinical Evidence

A double-blind, placebo-controlled RCT of 36 patients with recalcitrant plantar fasciitis found ultrasound-guided PRF at the posterior tibial nerve produced significant improvement in first-step pain, overall pain, AOFAS scores, and plantar fascia thickness vs control (all P ≤0.05). A network meta-analysis confirmed PRF demonstrated superior pain-relieving effects vs placebo at both 2–4 months and 6–12 months.

Dry Needling

Dry needling is effective for plantar fasciitis, with meta-analyses demonstrating significant pain reduction (VAS improvement 1.7–2.1 points) and functional improvement, particularly when added to routine treatments. Notably, dry needling provides superior long-term outcomes compared to corticosteroid injection (SMD 1.45 at 13–52 weeks), though effects may take at least 1 month to manifest.

Types of Dry Needling

1. Trigger Point Dry Needling (TrP-DN)

Targets myofascial trigger points in muscles associated with plantar heel pain. Target muscles include gastrocnemius, soleus, quadratus plantae, flexor digitorum brevis, abductor hallucis, and tibialis posterior.

Technique: 1 session/week for 4–6 weeks using 0.25–0.30 mm diameter solid filament needles; elicit local twitch responses using pistoning/fanning technique.

2. Electrical Dry Needling (EDN)

Combines dry needling with electrical stimulation at an 8-point standardised protocol (medial gastrocnemius, lateral gastrocnemius, soleus, quadratus plantae, flexor digitorum brevis, abductor hallucis, and two points in the plantar fascia). Electrical stimulation applied for 20 minutes per session over 6 sessions in 4 weeks.

A multicentre RCT of 111 patients found 78% successful outcome with EDN added to manual therapy, exercise, and ultrasound vs 21% without dry needling (P <0.001), with medium to large effect sizes.

3. Percutaneous Needle Tenotomy/Fasciotomy

An ultrasound-guided technique using an 18-gauge needle to repeatedly fenestrate the thickened, hypoechoic plantar fascia. Creates controlled microtrauma to stimulate healing. A meta-analysis of 35 studies (1,674 participants) showed VAS reduced from 7.3 to 1.5 at 1 year. Can be considered as an alternative to surgery.

Combining Dry Needling with Injections

Dry Needling + PRP

While direct evidence for this combination is limited, the mechanistic rationale is compelling: dry needling creates controlled microtrauma initiating the healing cascade, while PRP delivers concentrated growth factors to the injury site. The fenestration channels created by needling may enhance PRP distribution within the fascia. This combination may be considered in recalcitrant cases given the independent efficacy of both modalities.

Dry Needling + Corticosteroid

Not recommended. Dry needling aims to stimulate healing through controlled microtrauma, while corticosteroids inhibit the inflammatory response necessary for healing. Their mechanisms are opposing, and corticosteroids increase the risk of fascia rupture.

Dry Needling + Autologous Blood

A double-blinded RCT of 90 patients found that autologous blood injection added to dry needling provided no additional benefit over dry needling alone at any timepoint up to 26 weeks. Not recommended.

Adverse Events

Minor adverse events occur in approximately 32% of dry needling appointments (vs <1% sham): immediate needle insertion pain, transient increased heel pain, and delayed bruising. These are all minor and transient. No serious adverse events have been reported.

Prolotherapy

Dextrose prolotherapy is an effective regenerative injection therapy for chronic plantar fasciitis, with meta-analyses demonstrating significant pain reduction and functional improvement compared to placebo, particularly in the medium-term. According to a 2026 network meta-analysis of 63 RCTs, prolotherapy provides the most effective sustained pain relief among minimally invasive therapies.

Mechanism of Action

• Hypertonic dextrose causes controlled cellular dehydration and osmotic stress, triggering a localised inflammatory response that initiates wound healing
• Stimulates release of growth factors (PDGF, TGF-β, IGF-1) promoting fibroblast proliferation and collagen synthesis
• Analgesic effect is dextrose-dependent (≥5% concentration, >10 μL volume)

Efficacy

Injection Protocol

Solution Preparation

• 15% dextrose: 5 mL of 30% dextrose + 4 mL saline + 1 mL 2% lidocaine (most commonly used)
• 20% dextrose: 4 mL of 50% dextrose + 5 mL saline + 1 mL 2% lidocaine
• 25% dextrose: 5 mL of 50% dextrose + 4 mL saline + 1 mL 2% lidocaine

Technique

• Patient: prone or lateral decubitus; ankle in neutral to slight dorsiflexion (10–15°)
• Transducer: high-frequency linear array (10–15 MHz), longitudinal over the medial plantar heel
• Needle: 25–27 gauge, 38–50 mm, in-plane approach from the medial heel
• Target: perifascial space at the calcaneal insertion; may also target areas of maximal hypoechogenicity
• Volume: 3–5 mL per session; peppering technique recommended for focal distribution
• Frequency: 2–3 sessions at 3–4 week intervals (AAFP recommends 4–8 week intervals for at least 3 sessions)

Advantages over Corticosteroids

• More durable long-term outcomes without risks of fascia rupture or fat pad atrophy
• Comparable efficacy to PRP at significantly lower cost (no centrifugation or blood draw required)
• No serious complications reported in plantar fasciitis trials

Patient Counselling

Effects may take 1–3 months to manifest. Short-term results are inferior to corticosteroids, and patients should be counselled accordingly. Prolotherapy is most appropriate when long-term outcomes are prioritised over immediate relief.

TENS and Acupuncture

Transcutaneous Electrical Nerve Stimulation (TENS)

TENS produces analgesia through gate-control mechanisms, opioid receptor activation, and descending inhibitory pathway stimulation. High-frequency TENS (>50 Hz, typically 80–100 Hz) activates delta-opioid receptors; low-frequency TENS (≤10 Hz) activates mu-opioid receptors.

Evidence specifically for plantar fasciitis is limited. A large meta-analysis of 381 RCTs for chronic pain broadly showed moderate-certainty evidence of pain reduction during or immediately after treatment vs placebo. A related modality, noninvasive interactive neurostimulation (NIN), showed superior results to ESWT in one RCT of 104 patients with chronic plantar fasciitis (90% patient satisfaction).

TENS may be considered as an adjunctive home-based therapy given its low cost, safety, and ease of use. Effects peak during or immediately after use; particularly useful for acute pain flares.

Acupuncture

Acupuncture has stronger evidence than TENS for plantar fasciitis, with multiple RCTs demonstrating significant pain reduction.

Key Evidence

• RCT of 120 patients with chronic recalcitrant plantar fasciitis: 56.7% responders (≥50% pain reduction) in combined acupuncture groups vs 33.3% waitlist control (P = 0.02) at 4 weeks; 76.7% response rate at 16 weeks with high-intensity acupuncture; dose-response relationship confirmed
• RCT of 30 patients — electroacupuncture: 80% success rate (≥50% VAS reduction) vs 13.3% in control; VAS reduced from 6.0 to 1.9 vs 6.3 to 5.4 (P <0.001)
• Benefits typically manifest at 4–8 weeks; long-term durability beyond 16 weeks is less established

Electroacupuncture Protocol

• 10–12 sessions over 4–5 weeks, 2–3 times per week
• 30 minutes per session
• Frequency: 2–4 Hz (low frequency) or 80–100 Hz (high frequency)
• Key acupoints: PC 7 (Daling) — specific for heel pain; LI 4 (Hegu) — general analgesic point; local heel points

TENS vs Acupuncture Comparison

Trigger Point Locations and Needling Protocols

Trigger point dry needling may be useful where myofascial dysfunction contributes to persistent plantar heel pain. The most relevant muscles are usually those in the calf and intrinsic foot musculature, particularly the gastrocnemius, soleus, tibialis posterior, quadratus plantae, and flexor digitorum brevis, all of which can influence loading across the plantar fascia.

The clinical aim is to identify meaningful trigger points rather than needle every possible muscle. Treatment should focus on muscles that reproduce the patient’s pain pattern or are clearly contributing to excessive tension, altered gait, or local tenderness.

The technique involves insertion of a fine needle into the trigger point to reduce muscle tension and, where appropriate, elicit a local twitch response. In some cases, electrical stimulation may be added. As with other interventions, dry needling works best when it is incorporated into a wider treatment plan that includes stretching, strengthening, and correction of biomechanical contributors.

Care is needed when needling deeper or more proximal calf muscles, and technique should always reflect local anatomy, clinician experience, and patient tolerance.

Ultrasound-Guided Injection Technique for Prolotherapy

Anatomy

The plantar fascia comprises three fascial bands (medial, central, and lateral) originating from the medial calcaneal tubercle. The central band is thickest and most commonly affected. Key anatomical relationships include the flexor digitorum brevis (originates from the deep surface of the plantar fascia), Baxter’s nerve (traverses between FDB and quadratus plantae), and the plantar fat pad (superficial to the plantar fascia — must be avoided).

Sonographic Appearance

• Normal: hyperechoic, fibrillar structure; thickness <4 mm at calcaneal insertion
• Plantar fasciitis: thickened (≥4 mm), hypoechoic, loss of fibrillar pattern, possible perifascial oedema or calcifications

Equipment

• Ultrasound transducer: high-frequency linear array (10–15 MHz)
• Needle: 25–27 gauge, 38–50 mm
• Dextrose solution: 15–25% concentration (see preparation)
• Sterile gloves, drape, and antiseptic for standard aseptic technique

Patient Positioning

• Prone with foot hanging off the edge of the examination table (preferred), or
• Lateral decubitus with affected side up, or
• Supine with knee flexed and plantar surface accessible
• Ankle in neutral to slight dorsiflexion (10–15°) to tension and better visualise the plantar fascia

Injection Approaches

Peppering Technique

The peppering technique involves multiple small deposits of injectate at different locations within the target tissue, creating controlled microtrauma and distributing the dextrose solution throughout pathologic tissue:

• After initial needle placement, inject 0.5–1 mL
• Partially withdraw the needle (without exiting skin)
• Redirect to an adjacent area of pathology; inject another 0.5–1 mL
• Repeat 3–5 times, covering areas of maximal thickening/hypoechogenicity

Post-Procedure Care

• Apply pressure to injection site for 1–2 minutes
• Ice application for 15–20 minutes as needed for discomfort
• Relative rest for 24–48 hours; avoid high-impact activities for 1–2 weeks
• Continue stretching and strengthening exercises as tolerated
• Schedule next injection in 2–4 weeks; reassess pain, function, and ultrasound findings before each session

Surgical Management

Surgery is considered when nonsurgical treatment is ineffective after 6–12 months of comprehensive conservative management including ESWT.

Surgical Options

Gastrocnemius Recession (Recommended First Option)

Proximal medial gastrocnemius release (PMGR) is recommended as the first surgical option for recalcitrant plantar fasciitis to avoid potential biomechanical complications related to plantar fasciotomy. Patient satisfaction is 85.8%, comparable to open plantar fasciotomy (89.5%; P = 0.27). A meta-analysis of 5 RCTs showed significant improvements in AOFAS, VAS, and ankle dorsiflexion, with advantages over plantar fasciotomy in terms of postoperative recovery and preservation of fascial structure.

Partial Plantar Fasciotomy

• Patient satisfaction ranges from 48.8% to 89.5%
• Endoscopic approach provides better short-term outcomes and faster recovery than mini-open surgery
• Risks include: transient heel pad swelling, calcaneal fracture, posterior tibial nerve injury, flattening of longitudinal arch with midtarsal pain

When to Consider Surgery

Summary — Quick Reference for Clinicians

Patient Information Summary

Plantar fasciitis usually improves gradually rather than overnight. The most important part of treatment is to reduce excessive strain on the plantar fascia while keeping the foot moving and progressively restoring load tolerance. In most cases, complete rest is not helpful, but equally, trying to push through severe pain can delay recovery.

Supportive footwear should be used both indoors and outdoors. Walking barefoot on hard floors often aggravates symptoms and is best avoided while the heel is still irritable. Stretching of the plantar fascia and calf muscles should usually continue unless specific advice has been given to stop.

After corticosteroid injection

Patients can usually walk straight away, but activity should be sensible for the first 24–48 hours. A short period of relative rest is appropriate, followed by gradual return to normal walking. High-impact exercise, running, jumping, or long walks should be avoided for around 1–2 weeks, particularly if the pain settles quickly, as symptom relief can occur before the fascia has adapted.

After PRP injection

Walking is usually allowed immediately for basic daily activities, but significant activity should be avoided for about 1 week. Anti-inflammatory medication should usually be avoided for 2–4 weeks after the procedure. Gentle stretching commonly resumes between days 2 and 7, strengthening exercises usually begin around weeks 2 to 3, and fuller exercise is usually reintroduced gradually at around 4–6 weeks depending on symptoms and progress. Running and impact exercise should therefore be delayed until the fascia is settling and loading has been rebuilt progressively.

After botulinum toxin injection

Walking for normal day-to-day activity is usually allowed immediately. Stretching and rehabilitation can generally continue, but strenuous impact loading should still be increased gradually rather than resumed all at once. Return to exercise is guided by symptoms.

After prolotherapy

Walking is usually allowed for normal daily activities, but patients should expect that the benefit is slower than with steroid injection. Some soreness is common in the early phase. Improvement may take 1–3 months to become clear, and repeated sessions may be required. High-impact activity should be reduced initially and reintroduced gradually as symptoms improve.

Across all treatments, the overall goal is not simply to rest the heel, but to return to walking, strengthening, and then higher-level exercise in a structured and progressive way.

Plantar Fasciitis Treatment at Pain Spa

Pain Spa offers a comprehensive and individualised pathway for plantar fasciitis, recognising that persistent plantar heel pain may be mechanical, degenerative, myofascial, neuropathic, or mixed. Assessment and treatment are tailored accordingly, with ultrasound guidance used where appropriate to improve precision and safety.

Procedures offered at Pain Spa include:

• ✔Ultrasound-guided corticosteroid injections
• ✔Platelet-rich plasma (PRP) injections
• ✔Botulinum toxin (Botox) injections
• ✔Dry needling
• ✔Ultrasound-guided prolotherapy
• ✔Tibial nerve blocks
• ✔Baxter’s nerve blocks
• ✔Medial calcaneal nerve blocks
• ✔Pulsed radiofrequency (PRF) treatment
• ✔Radiofrequency treatment for selected refractory cases

The focus is not simply on short-term pain relief, but on identifying the dominant pain mechanism and matching treatment to the underlying pathology, alongside rehabilitation and activity guidance designed to support long-term recovery.